文献
J-GLOBAL ID:201702282477168250
整理番号:17A1390160
2型糖尿病と確立した心血管疾患患者における尿中アルブミン-クレアチニン比に対するエンパグリフロジンの効果:EMPA REG OUTCOME無作為化プラセボ対照試験からの探索的分析【Powered by NICT】
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
著者 (8件):
Cherney David Z I
(Department of Medicine and Department of Physiology, Division of Nephrology, University Health Network, University of Toronto, Toronto, ON, Canada)
,
Cherney David Z I
(Toronto General Hospital, Toronto, ON, Canada)
,
Zinman Bernard
(Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada)
,
Inzucchi Silvio E
(Section of Endocrinology, Yale School of Medicine, New Haven, CT, USA)
,
Koitka-Weber Audrey
(Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany)
,
Mattheus Michaela
(Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim, Germany)
,
von Eynatten Maximilian
(Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim, Germany)
,
Wanner Christoph
(Division of Nephrology, Wuerzburg University Clinic, Wuerzburg, Germany)
資料名:
Lancet Diabetes & Endocrinology
(Lancet Diabetes & Endocrinology)
巻:
5
号:
8
ページ:
610-621
発行年:
2017年
JST資料番号:
W3110A
ISSN:
2213-8587
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)